Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

IAVI

- PMLiVE

GSK’s Arexvy RSV vaccine receives expanded EC approval for use in adults

RSV affects approximately 64 million people around the world each year

- PMLiVE

FDA approves Pfizer and BioNTech’s jab for COVID-19

Globally, five billion doses of the companies’ vaccine have been distributed

- PMLiVE

J&J’s multidrug-resistant TB treatment Sirturo granted full EC and FDA approvals

An estimated 410,000 people globally developed multidrug- or rifampicin-resistant TB in 2022

- PMLiVE

CureVac advances ‘promising’ seasonal flu mRNA vaccine to phase 2 development

The mid-stage study of the candidate is expected to begin in the fourth quarter of 2023

- PMLiVE

Gates Foundation and Wellcome to fund late-stage trial of tuberculosis vaccine candidate

If proven effective, M72 could be the first new tuberculosis vaccine in over a century

- PMLiVE

Gates MRI and Calibr announce licensing agreement for tuberculosis treatment

TB is a severe disease responsible for an estimated 1.5 million deaths per year

- PMLiVE

WHO to establish tuberculosis vaccine accelerator council

An estimated 10.6 million contracted TB in 2021, with the disease causing 1.6 million deaths

- PMLiVE

Pfizer’s RSV vaccine candidate accepted for FDA priority review for use in older adults

A phase 3 study showed the vaccine was 85.7% effective in those with three or more symptoms

- PMLiVE

Moderna’s bivalent Omicron-targeting boosters show superiority to original COVID-19 vaccine

Both boosters produced a better immune response against Omicron BA.4/BA.5 subvariants

- PMLiVE

Pfizer’s maternal RSV vaccine candidate shows promise in phase 3 trial

The company stopped the trial early and plans to file for US approval by the end of 2022

- PMLiVE

GSK’s respiratory syncytial virus older adult vaccine given Priority Review by FDA

There are currently no RSV vaccines approved for older adults anywhere worldwide

- PMLiVE

GSK’s application for its RSV vaccine accepted by EMA under accelerated assessment

The vaccine demonstrated overall efficacy of 82.5% in adults aged 60 years and older

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links